Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results

M. De Lena, A. De Mitrio, A. Catino, V. Lorusso, M. Brandi

Research output: Contribution to journalArticle

Abstract

Fifteen patients with advanced ovarian cancer who progressed or relapsed after initial cisplatinum-based treatment were admitted into a phase II study with oral lonidamine in association with a weekly cisplatin schedule. One complete and four partial clinical responses were observed (5/15:33%). Stable disease and progression were observed in 1 and 9 cases, respectively. The activity demonstrated in refractory or early relapsed patients (14% and 50% objective responses, respectively), together with the good feasibility and tolerability support the clinical use of this regimen, at least as salvage therapy. However, an increased number of patients are needed to better define the role played by lonidamine in the reversal of cisplatin resistance in ovarian cancer and in other tumors.

Original languageEnglish
Pages (from-to)779-782
Number of pages4
JournalInternational Journal of Oncology
Volume4
Issue numberSUPPL.
Publication statusPublished - 1994

Keywords

  • advanced ovarian cancer
  • carboplatin
  • cisdiamminedichloroplatinum
  • lonidamine
  • reversal of drug resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results'. Together they form a unique fingerprint.

  • Cite this